What Йодид 200 Treats: Main Uses and Benefits

Symptomatic Management and Stability

The primary therapeutic use of Йодид 200 is applied across domains where additional symptomatic support is needed in contexts involving systemic imbalance related to insufficient iodine. This medicine is commonly used to help with conditions marked by systemic imbalance, relevant when supportive symptom management is appropriate.

This medicine is used for managing symptom clusters related to iodine-deficiency goitre. It provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of noticeable physiological strain linked to this condition. Йодид 200 is relevant when supportive symptom management is appropriate for conditions presenting with acute episodes. This use assists with maintaining functional stability when symptoms intensify temporarily.

It is commonly used for the prevention of deficiency manifestations, especially during phases of life with heightened metabolic needs.

Quick Fact: Targeted Symptomatic Support

Eligibility for Йодид 200 (Potassium Iodide)

This medicine is contraindicated and must not be used by individuals with a known hypersensitivity or allergy to the active substance or any of the product's excipients.

Contraindicated/Prohibited Populations:

• Patients with manifest hyperthyroidism (an overactive thyroid condition).
• Individuals with the chronic skin diseases Dermatitis Herpetiformis (Dühring-Brocq disease) or Hypocomplementaemic Vasculitis.

Restricted and Special Consideration Populations:

Population Group	Eligibility Status
Children & Adolescents	Allowed. Use is established across all pediatric age groups, although dosage is age-dependent.
Pregnant & Lactating Women	Allowed for indicated use, but generally restricted to a single dose to minimize risk to the fetus/infant, especially with active hyperthyroidism. Thyroid function monitoring for the neonate is recommended.
Older Adults (over 60 years)	Restricted to a single dose only, due to a higher risk of pre-existing, undiagnosed thyroid conditions.
Renal Impairment	Requires special caution and close monitoring, as potassium salts can increase the risk of hyperkalemia.
Latent Thyroid Disease	Patients with suspected hyperthyroidism, autonomous thyroid function, or nodular goiter are at increased risk of iodine-induced hyperthyroidism and require caution/medical supervision.

Interactions with other medicines and products

Interactions with Йодид 200 (Potassium Iodide) are primarily focused on its effect on the thyroid gland and the potassium content of the salt. Patients must be aware of combinations that may affect these systems.

Pharmacodynamic and Electrolyte Interactions

Interacting Substance/Class	Documented Interaction Effect
Anti-thyroid drugs (e.g., Carbimazole, Propylthiouracil)	Additive effect on suppressing thyroid hormone production, increasing the risk of hypothyroidism and goiter.
Lithium preparations	May lead to additive hypothyroid and goitrogenic effects.
ACE Inhibitors and Potassium-Sparing Diuretics (e.g., Amiloride)	Increased risk of hyperkalemia (elevated potassium levels) due to the potassium component of the drug.

Interactions Affecting Thyroid Uptake

Concurrent use with radioactive iodine (I-131) for diagnostic or therapeutic purposes requires specific management. Potassium iodide administration may significantly block the thyroid's uptake of radioactive iodine, potentially reducing the effectiveness of the radiation therapy. Consequently, regulatory guidance often specifies precise time separation or withholding requirements for these agents. The drug may also require timing separation from other iodine-containing radiopharmaceuticals.

How Йодид 200 Works: The Mechanism

The physiological action of stable iodide relies on the competitive blockade of the Sodium/Iodide Symporter (NIS), a dedicated transporter protein located on the membrane of thyroid follicular cells. The mechanism requires achieving a high plasma concentration of stable iodide, which saturates the NIS. This competitive inhibition effectively arrests the mechanism by which the thyroid gland concentrates all iodide species.

This saturation immediately halts the Thyroidal Iodide Trapping Pathway, restricting the incorporation of iodide into the cell's hormone-synthesis machinery. The radioactive iodide is thereby forced to remain in the systemic circulation, leading to its rapid renal clearance. This suppression of the uptake pathway is the central physiological step that ultimately reduces the concentration of radioactive iodide within the tissue.

The functional consequence is governed by concentration-dependent saturation kinetics. Since the action is purely preventative, the mechanism becomes functionally constrained and weaker if the radioactive isotope has already been significantly concentrated and incorporated by the gland before the competitive blockade is fully established.

How to Use Йодид 200

The administration of Йодид 200 (Potassium Iodide, KI) is strictly defined by regulatory documents, particularly concerning its primary use for thyroid blocking during a radiation emergency. The medicine is taken via the oral route and is available in tablet forms (65 mg and 130 mg) and as an oral solution.

---

Official Administration Protocol

Administration of Potassium Iodide for radiation protection is not elective; it occurs only when explicitly directed by national or local public health and emergency management authorities. The protocol is time-sensitive, requiring the dose to be taken as soon as possible after the instruction is given, as effectiveness diminishes significantly if taken more than 24 hours after exposure.

Population Group	Standard Labeled Dose (KI)	Frequency Pattern
Adults (≥ 12 years & ≥ 150 lbs)	130 mg	Once every 24 hours
Children (3–12 years)	65 mg	Once every 24 hours
Infants (1 month to 3 years)	32.5 mg	Once every 24 hours

For those who cannot swallow tablets, the medication may be crushed or chewed and mixed with liquids, such as water, milk, or juice. It is generally recommended to take the dose with food or milk to help minimize potential stomach irritation. A single dose provides thyroid protection for approximately 24 hours, and any subsequent doses are dependent on the continuing instruction of public health officials.

Potassium Iodide is also labeled for use as an expectorant in non-emergency medical contexts, with an adult solution dose typically ranging from 300 mg to 600 mg, administered three to four times daily.

Research evidence / Overview of studies for Йодид 200

---

Evidence for use in Preventing Iodine Deficiency (Goiter Prophylaxis)

This section will summarize the clinical studies, including large-scale population studies and smaller trials, that have investigated the patterns observed with Йодид 200 (Potassium Iodide) in research exploring iodine deficiency and the formation or recurrence of a goiter (enlarged thyroid gland).

Research has extensively examined the use of iodine-containing preparations like Йодид 200 in research exploring goiter occurrence—a condition marked by an enlarged thyroid gland—in populations that have insufficient iodine intake in their diet. The findings describe patterns observed in the studies where supplementing iodine intake was one factor examined in relation to the occurrence of goiter in children and adolescents in areas known for iodine deficiency.

Evidence for use in Treating Goiter (Diffuse Euthyroid Struma)

This part will outline the key research, such as controlled clinical trials, that examined Йодид 200 in individuals with existing goiter (diffuse euthyroid struma) in various age groups, detailing the typical study designs and reported outcomes regarding thyroid size and function.

Studies have examined iodine supplementation in individuals with an existing goiter when it is classified as "euthyroid." The data show patterns related to changes in goiter size that were observed in some individuals who received iodine in the studies, especially in younger patients. Follow-up durations were limited in many of these trials.

Long-term Studies and Follow-up

Research has examined long-term iodine supplementation primarily in the context of large public health prevention efforts. This evidence contributes to understanding symptom patterns by describing the sustained patterns observed with iodine in research related to deficiency and goiter patterns. The information about the durability of response after observation for an existing goiter is stopped is often less clear.

What is Still Uncertain about Йодид 200

Evidence quality varies across studies regarding the optimal dosage and duration for individual use in research. Findings were mixed across different regions. The comparative evidence is lacking to definitively show whether Йодид 200 is better or worse than other approaches. The existing evidence highlights what is known — and what is still uncertain — about using iodine for various thyroid-related concerns.

Common questions about Йодид 200 (FAQ)

---

Q: Is it possible to take Iodide 200 for prophylaxis even if there is no obvious deficiency?

Regulatory documents indicate that the medication is labeled for the prophylaxis of goiter, which is the enlargement of the thyroid gland due to iodine deficiency. This information comes from the context of endemic goiter where iodine intake in the diet is insufficient. The official use is linked to addressing the risk of such deficiency-related conditions.

---

Q: How long should Iodide 200 usually be taken?

The duration of taking this medication is highly dependent on the reason for its use. For its primary use in radiation emergencies, the frequency pattern is defined by public health officials (often a 24-hour interval). For other labeled uses, such as goiter prevention, the official product information may describe treatment courses lasting several months.

---

Q: After what time can one expect Iodide 200 to start working?

In the context of a radiation emergency, official guidance states that the medication should be taken as soon as possible after instructions are given. This timing is crucial as the protective function is described as significantly diminished if it is taken more than 24 hours after exposure to the radioactive isotope.

---

Q: Is it true that Iodide 200 can help with pregnancy planning?

Official information highlights that the use of Potassium Iodide during pregnancy is allowed for indicated purposes due to the element's necessity for the proper development of the fetal thyroid gland. While iodine is essential, official drug labeling addresses use during pregnancy and lactation, not specifically the pre-conception planning phase.

---

Q: Why does one sometimes experience a feeling of heaviness in the stomach when taking Iodide 200?

Gastrointestinal disturbances, such as nausea, vomiting, or stomach pain, are among the possible side effects described in official product information. This information also mentions that taking the medication with food or milk is a common strategy described to help minimize this potential stomach irritation.

---

Q: What is known about the safety of Iodide 200 for long-term use?

Regulatory documents indicate that prolonged or inappropriate use of Potassium Iodide may rarely lead to the development of thyroid issues, specifically hyperthyroidism or hypothyroidism. Caution is advised for specific populations, and repeat dosing for radiation protection is generally restricted for infants and older adults.

---

Q: Why do doctors often recommend Iodide 200 to pregnant women?

Official guidance indicates that iodine is an essential element, playing a necessary role in supporting thyroid function. For pregnant women, this is related to ensuring proper development of the fetal thyroid gland.

---

Q: Is a break necessary after a course of Iodide 200?

Official product information defines the duration for which the medication is intended to be used for its non-emergency indications, which determines the end of the treatment course. The focus of the information is on the prescribed period of administration.

---

Q: Why do some people think Iodide 200 'doesn't work'?

The regulatory explanation for the drug's mechanism of action is based on saturating the thyroid gland to prevent the uptake of radioactive iodine. Its protective effectiveness is described as being severely limited if the medication is taken too late, specifically more than 24 hours after exposure to the radioactive isotope.

---

Q: What are 'iodine deficiency conditions' in the context of using Iodide 200?

Official documentation indicates that Potassium Iodide is used for the prophylaxis, or prevention, of goiter—which is an enlarged thyroid gland—caused by iodine deficiency. Therefore, 'iodine deficiency conditions' refers to states where inadequate iodine intake leads to thyroid issues like goiter.

Official Storage and Disposal Requirements

Йодид 200 (Potassium Iodide) must be stored strictly according to regulatory labeling to maintain its stability.

Storage Component	Requirement
Temperature	Store at room temperature, below 25 C; do not freeze or store near heat.
Protection	Keep in the original container or carton, protected away from moisture and direct light.
Child Safety	The medicine must be stored out of the reach of children.
Stability Note	Do not use the oral solution if it has turned brownish yellow.

Disposal instructions mandate that unused or expired tablets must be discarded in regular household garbage. The medicine must not be flushed down the toilet or placed into the water supply, and disposal should align with local requirements for pharmaceutical waste.